Laigo Bio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $19.8M

  • Investors
  • 11

Laigo Bio General Information

Description

Developer of a biotechnology platform designed to develop dual-targeted therapies through protein degradation. The company's platform focuses on developing a biological approach to treat tumors and neurological diseases by targeting chimeric molecules via surface removal, enabling medical professionals to achieve sustained degradation of target receptors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Jaarbeursplein 6
  • 3521 AL Utrecht
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Jaarbeursplein 6
  • 3521 AL Utrecht
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Laigo Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 20-Mar-2026 $19.8M Completed Generating Revenue
2. Grant 28-Jul-2022 Completed Generating Revenue
1. Seed Round 08-Feb-2022 Completed Generating Revenue
To view Laigo Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Laigo Bio Patents

Laigo Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025206956-A1 Bispecific antigen binding proteins Pending 12-Jan-2024
WO-2025149633-A1 Bispecific antigen binding proteins Inactive 12-Jan-2024

Laigo Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Laigo Bio Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angelini Ventures Corporate Venture Capital Minority
Biovance Capital Partners Venture Capital Minority
Cancer Research Technology Venture Capital Minority
Curie Capital Venture Capital Minority
Eurazeo Asset Manager Minority
You’re viewing 5 of 11 investors. Get the full list »

Laigo Bio FAQs

  • When was Laigo Bio founded?

    Laigo Bio was founded in 2021.

  • Where is Laigo Bio headquartered?

    Laigo Bio is headquartered in Utrecht, Netherlands.

  • What is the size of Laigo Bio?

    Laigo Bio has 3 total employees.

  • What industry is Laigo Bio in?

    Laigo Bio’s primary industry is Drug Discovery.

  • Is Laigo Bio a private or public company?

    Laigo Bio is a Private company.

  • What is Laigo Bio’s current revenue?

    The current revenue for Laigo Bio is .

  • How much funding has Laigo Bio raised over time?

    Laigo Bio has raised $19.8M.

  • Who are Laigo Bio’s investors?

    Angelini Ventures, Biovance Capital Partners, Cancer Research Technology, Curie Capital, and Eurazeo are 5 of 11 investors who have invested in Laigo Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process